Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct;75(10):1043-1050.
doi: 10.1055/s-0035-1558054.

Gestational Trophoblastic Disorders: An Update in 2015

Affiliations
Review

Gestational Trophoblastic Disorders: An Update in 2015

F T Stevens et al. Geburtshilfe Frauenheilkd. 2015 Oct.

Abstract

Gestational trophoblastic diseases (GTD) are a group of pregnancy-related disorders representing rare human tumours. They encompass premalignant disorders including complete (CHM), partial hydatidiform mole (PHM), exaggerated placental site (EPS), and placental-site nodule (PSN) as well as malignant disorders (also known as "gestational trophoblastic neoplasia [GTN]") including invasive mole, choriocarcinoma (CC), placenta-site trophoblastic tumour (PSTT), and epitheloid trophoblastic tumours (ETT) (Fig. 1). Originally, GTD develop from abnormal proliferation of trophoblastic tissue and form botryoid arranged vesicles. Premalignant moles are usually treated by suction curettage while persistent and recurrent moles and malignant forms require systemic therapy with methotrexate or combination chemotherapy consisting of etoposide, actimomycin D, methotrexate, vincristine, and cyclophosphamide (EMA-CO). β-human chorion gonadotropin (β-hCG) plays a crucial role in diagnosis and monitoring therapeutic effects. Since the definitive diagnosis cannot be obtained by histology in most cases, persistent or recurrent disease is diagnosed by elevated or persistent serum levels of β-hCG. While curing rates are described to be as high as 98 %, GTD may initially present, recur, or end up as a metastasising systemic disease. This underlines the importance of a regular and consistent follow-up after treatment.

Gestationsbedingte Trophoblasterkrankungen (GTE) gehören zu der Gruppe seltener menschlicher Tumoren, die im Rahmen einer Schwangerschaft entstehen. Diese Gruppe umfasst prämaligne Veränderungen wie Blasenmole und Partialmole, hyperplastische Implantationsstelle des Plazentabetts (exaggerated placental site, EPS) und Plazentabettknötchen (placental site nodule, PSN) sowie maligne Erkrankungen (auch gestationsbedingte Trophoblastneoplasien [GTN] genannt) wie invasive Molen, Chorionkarzinom, Plazentabetttumor (placental site trophoblastic tumor, PSTT) und epitheloider Trophoblasttumor (ETT) (Abb. 1). Die Entstehung von GTE ist durch die abnorme Proliferation von Trophoblastzellen gekennzeichnet, die traubenförmig angeordnete Bläschen bilden. Prämaligne Molen werden zumeist mit Saugkürettage therapiert. Die Behandlung persistierender und rezidivierender Molen sowie maligner Formen besteht aus einer systemischen Therapie mit Methotrexat oder einer Kombinationschemotherapie aus Etoposid, Actinomycin-D, Methotrexat, Vincristin, und Cyclophosphamid (EMA-CO). β-humanes Choriongonadotropin (β-hCG) spielt eine wichtige Rolle bei der Diagnose und Kontrolle der Therapie. Da eine histologische Untersuchung in den meisten Fällen keine endgültige Diagnose liefert, beruht die Diagnose von Persistenz und Rezidiv auf erhöhten (persistierenden) Serumkonzentrationen von β-hCG. Obwohl die in der Literatur angegebenen Heilungsraten hoch sind mit bis zu 98 %, können GTE nach dem ersten Auftreten rekurrieren oder in eine systemische Erkrankung mit Metastasierung übergehen. Dies unterstreicht die Bedeutung einer regelmäßigen und konsequenten Nachsorge.

Keywords: gestational neoplasia; gestational trophoblastic disease; human chorion gonadotropin; hydatidiform moles; molar pregnancy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None.

Figures

Fig. 1
Fig. 1
Classification of gestational trophoblastic disease.
Fig. 2
Fig. 2
Duplex ultrasonography of a GTN following a CHM.
Fig. 3 a
Fig. 3 a
to d Pathogenesis of CHM, PHM and rare familial recurrent hydatidiform mole; CHM = complete hydatidiform mole, PHM = partial hydatidiform mole. Paternal (white) and maternal (black) derived genes are shown.
Fig. 4
Fig. 4
Complete hydatidiform mole, haematoxin-eosin staining, original magnification × 100 (with kind permission of Prof. Gabbert, Department of Pathology, Heinrich-Heine-University Düsseldorf).
Fig. 5
Fig. 5
Partial hydatidiform mole, haematoxin-eosin staining, original magnification × 50 (with kind permission of Prof. Gabbert, Department of Pathology, Heinrich-Heine-University Düsseldorf).
Fig. 6
Fig. 6
Choriocarcinoma, haematoxin-eosin staining, original magnification × 200, (with kind permission of Prof. Gabbert, Department of Pathology, Heinrich-Heine-University Düsseldorf).
Fig. 7
Fig. 7
Magnetic resonance imaging of an intramural GTN (with kind permission of Prof. Antoch, Department of Radiology, Heinrich-Heine-University Düsseldorf).

Similar articles

Cited by

References

    1. Seckl M J, Sebire N J, Berkowitz R S. Gestational trophoblastic disease. Lancet. 2010;376:717–729. - PubMed
    1. Palmer J R. Advances in the epidemiology of gestational trophoblastic disease. J Reprod Med. 1994;39:155–162. - PubMed
    1. Ngan S, Seckl M J. Gestational trophoblastic neoplasia management: an update. Curr Opin Oncol. 2007;19:486–491. - PubMed
    1. Seckl M J, Fisher R A, Salerno G. et al.Choriocarcinoma and partial hydatidiform moles. Lancet. 2000;356:36–39. - PubMed
    1. Fisher R A, Lawler S D, Povey S. et al.Genetically homozygous choriocarcinoma following pregnancy with hydatidiform mole. Br J Cancer. 1988;58:788–792. - PMC - PubMed